BioCryst To Present Peramivir Trial Results For The Treatment Of Influenza At The ICAAC 2014 Meeting
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the presentation of trial results related to intravenous (I.V.) peramivir for the treatment of influenza at the Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC) in Washington, D.C., September 5-9, 2014.
Peramivir presentations during the ICAAC Conference include:
Poster Presentation Number A-012 titled "Single Dose Injections of IV and IM Peramivir Are Bioequivalent and Well Tolerated," by G. Atiee, et al, is scheduled for Saturday, September 6, at 10:00 A.M.-12:00 P.M., Eastern Daylight Time.
Oral Slide Presentation Number V-1297 titled "Single Dose Peramivir for the Treatment of Acute Seasonal Influenza: Integrated Analysis of Efficacy and Safety from Two Placebo-controlled Trials," by R. Whitley et al, is scheduled for Monday, September 8, at 8:45-9:00 A.M., Eastern Daylight Time.
Copies of the abstracts are available and can be viewed online through the ICAAC website at www.icaac.org. The oral presentation and poster will be uploaded to the BioCryst website upon completion of the sessions to abide by the conference's embargo policy. Please refer to the Company's peramivir publications page.
The peramivir New Drug Application (NDA) for the indication of treatment of acute uncomplicated influenza in adults is currently under regulatory review by FDA, with a Prescription Drug User Fee Application (PDUFA) date of Dec 23, 2014. If approved, peramivir would be marketed as RAPIVAB™ (peramivir injection).
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.